The team at BioWorld wrote a detailed article on our Phase 2/3 RT001 study readout, highlighting the statistically significant survival benefits of treatment as compared to control. You can see a reprint of the piece in the following PDF.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue.